Cerebrolysin
Neuropeptide preparation derived from purified porcine brain tissue; demonstrates neurotrophic-mimetic activity including BDNF-like and NGF-like effects on cortical neurons in culture.
Cerebrolysin is a peptide preparation derived from purified porcine brain tissue, manufactured by Ever Neuro Pharma in Austria since the 1970s. The product is a defined mixture of low-molecular-weight peptides (under 10 kDa, comprising ~15-25% of the preparation by weight) and free amino acids, with batch-to-batch consistency maintained by chromatographic standardization.
Across preclinical models, Cerebrolysin demonstrates neurotrophic-mimetic activity: enhancement of dendritic arborization, protection of neurons against glutamate excitotoxicity, anti-apoptotic effects, and partial substitution for BDNF and NGF in survival assays. Imaging-based clinical studies have reported reductions in infarct volume and improvements in functional recovery scores after ischemic stroke when Cerebrolysin is administered within a defined post-stroke window.
Cerebrolysin is approved for stroke, traumatic brain injury, and certain forms of cognitive decline in over 50 countries (predominantly in Europe and Asia). It is not approved by the FDA. The PharmaKinetics database catalogs it for research and reference purposes alongside other peptide preparations under active investigation.